Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 40Cisplatin 37Pemetrexed 33Radiotherapy 23Paclitaxel 22pembrolizumab 20durvalumab 19Docetaxel 19Gemcitabine 18Nivolumab 15Radiosurgery 14Etoposide 13atezolizumab 11Erlotinib Hydrochloride 11Taxes 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Bevacizumab 8Cyclophosphamide 7Platinum 6Gefitinib 6Surveys and Questionnaires 5Biopsy 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5sotorasib 4Ramucirumab 4Radiation 4Immunotherapy 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Toll-Like Receptor 1 × Thoracic × Clear all
NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡